Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L. Friedman, Éric Lefebvre, Geoffrey C. Farrell et al.|Hepatology|2017Cited by 657
Liquid Chromatography−Mass Spectrometry-Based Parallel Metabolic Profiling of Human and Mouse Model Serum Reveals Putative Biomarkers Associated with the Progression of Nonalcoholic Fatty Liver DiseaseJonathan Barr, José M. Mato, Mercedes Vázquez–Chantada et al.|Journal of Proteome Research|2010Cited by 165